Kim YN, Joung JG, Park E, Kim JW, et al. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045. Int J Cancer 2023 Aug 21. doi: 10.1002/ijc.34696.
PMID: 37602928